GSK

GSK’s lung cancer drug shows 94% response rate in frontline trial

GSK presented data on Monday at the 2026 World Conference on Lung Cancer in Seoul showing that its ROS1 inhibitor Jideytro, known generically as zidesamtinib, produced a 94% objective response rate in patients with advanced ROS1-positive non-small cell lung cancer…

GSK lung cancer drug cuts death risk by 54% in pivotal trial

GSK reported on Sunday that its cancer drug risvutatug rezetecan, known as Ris-Rez, reduced the risk of death by 54% compared with standard treatment in patients with relapsed small cell lung cancer, results that sent the company's shares higher at…

AstraZeneca, GSK strike deals with Sino Biopharma amid U.S. scrutiny

AstraZeneca and GSK announced separate partnerships with China's Sino Biopharmaceutical on Wednesday, marking a flurry of cross-border pharmaceutical dealmaking even as U.S. lawmakers push to bring such transactions under national security review.